Literature DB >> 24064023

Familial Mediterranean fever: a critical digest of the 2012-2013 literature.

Eli M Eisenstein1, Yakov Berkun, Eldad Ben-Chetrit.   

Abstract

The year 2012-2013 has been a fertile one in the area of FMF inquiry. Recent studies have led to further insight into the possible mechanisms whereby pyrin mutations might cause the auto-inflammatory phenotype that is characteristic of FMF. Evidence-based guidelines for diagnosis of FMF, including the role of genetic testing, have become available. Risks for colchicine resistance have been partially defined, and a randomised, controlled trial showing efficacy of an interleukin-1 antagonist for treatment of colchicine-resistant or intolerant FMF patients was reported. In this review, we summarise these and other salient findings from the recent FMF literature, and discuss their significance for the clinician.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24064023

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients.

Authors:  Sinem Yalcıntepe; Ozturk Ozdemır; Coskun Sılan; Filiz Ozen; Ahmet Uludag; Ferhan Candan; Fatma Sılan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-03       Impact factor: 2.441

2.  Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center.

Authors:  Ayşe Tanatar; Hafize Emine Sönmez; Şerife Gül Karadağ; Figen Çakmak; Mustafa Çakan; Ferhat Demir; Betül Sözeri; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2019-10-23       Impact factor: 2.631

3.  Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern.

Authors:  Esvet Mutlu; Mete Eyigör; Derya Mutlu; Meral Gültekin
Journal:  Cent Eur J Immunol       Date:  2016-03-24       Impact factor: 2.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.